There are 2789 resources available
609P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
Presenter: Stephen Freedland
Session: ePoster Display
611P - Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
Presenter: Emmanuel Antonarakis
Session: ePoster Display
613P - Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niamh Keegan
Session: ePoster Display
614P - Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance
Presenter: J.S. de Bono
Session: ePoster Display
615P - Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Giorgia Gurioli
Session: ePoster Display
616P - Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
Presenter: Daniel George
Session: ePoster Display
690P - Comprehensive genomic profiling (CGP) of VHL mutated and VHL wild type clear cell renal cell carcinoma (ccRCC)
Presenter: Gennady Bratslavsky
Session: ePoster Display
716TiP - IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
Presenter: Thomas Powles
Session: ePoster Display